Smith & Nephew's Guidance Cut Implies Very Weak Organic Growth
Dow Jones11-04
1109 GMT - Smith & Nephew's third-quarter update was worse than expected as the guidance cut suggests a downgrade to consensus expectations, UBS says. The medical technology company's third-quarter organic growth was roughly in line with consensus, but the guidance cut implies a 2% cut to 2026 consensus trading profit forecasts, the analysts say. The organic growth rate for the fourth quarter is implied at 3.9%, which when adjusted for trading days is "very weak" at 2.3%, they add. UBS notes that the company's statement about considering strategic options for its orthopedics unit doesn't imply any immediate action for the business, following investor optimism that this would be the case. Shares are down 0.45%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments